RESUMEN
ABSTRACT: A 72-year-old woman was referred for whole-body 111In-pentetreotide scintigraphy with SPECT/CT. There was increased uptake of lymphadenopathy in the left axilla and left deltoid muscle. The patient's history revealed that the patient received the first dose of the COVID-19 vaccine 3 days before the 111In-pentetreotide scintigraphy with SPECT/CT. This case demonstrates that the COVID-19 vaccine can cause 111In-pentetreotide uptake in the lymph nodes and the deltoid muscle.
Asunto(s)
Vacunas contra la COVID-19 , Radioisótopos de Indio/metabolismo , Somatostatina/metabolismo , Anciano , COVID-19 , Músculo Deltoides/metabolismo , Femenino , Humanos , Ganglios Linfáticos/metabolismo , Somatostatina/análogos & derivados , Tomografía Computarizada por Rayos X , VacunaciónRESUMEN
The Arg-Gly-Asp (RGD) peptide shows a high affinity for αvß3 integrin, which is overexpressed in new tumor blood vessels and many types of tumor cells. The radiolabeled RGD peptide has been studied for cancer imaging and radionuclide therapy. We have developed a long-term tumor-targeting peptide DOTA-EB-cRGDfK, which combines a DOTA chelator, a truncated Evans blue dye (EB), a modified linker, and cRGDfK peptide. The aim of this study was to evaluate the potential of indium-111(111In) radiolabeled DOTA-EB-cRGDfK in αvß3 integrin-expressing tumors. The human glioblastoma cell line U-87 MG was used to determine the in vitro binding affinity of the radiolabeled peptide. The in vivo distribution of radiolabeled peptides in U-87 MG xenografts was investigated by biodistribution, nanoSPECT/CT, pharmacokinetic and excretion studies. The in vitro competition assay showed that 111In-DOTA-EB-cRGDfK had a significant binding affinity to U-87 MG cancer cells (IC50 = 71.7 nM). NanoSPECT/CT imaging showed 111In-DOTA-EB-cRGDfK has higher tumor uptake than control peptides (111In-DOTA-cRGDfK and 111In-DOTA-EB), and there is still a clear signal until 72 h after injection. The biodistribution results showed significant tumor accumulation (27.1 ± 2.7% ID/g) and the tumor to non-tumor ratio was 22.85 at 24 h after injection. In addition, the pharmacokinetics results indicated that the 111In-DOTA-EB-cRGDfK peptide has a long-term half-life (T1/2λz = 77.3 h) and that the calculated absorbed dose was safe for humans. We demonstrated that radiolabeled DOTA-EB-cRGDfK may be a promising agent for glioblastoma tumor imaging and has the potential as a theranostic radiopharmaceutical.
Asunto(s)
Quelantes/metabolismo , Glioblastoma/metabolismo , Oligopéptidos/metabolismo , Animales , Línea Celular Tumoral , Compuestos Heterocíclicos con 1 Anillo/metabolismo , Xenoinjertos/metabolismo , Humanos , Radioisótopos de Indio/metabolismo , Ratones , Ratones Endogámicos NOD , Ratones SCID , Imagen Molecular/métodos , Péptidos Cíclicos/metabolismo , Radiofármacos/metabolismo , Ratas , Distribución TisularRESUMEN
ABSTRACT: A 55-year-old woman with multiple medical problems, including anuric, dialysis-dependent, end-stage renal disease, presented with persistent fever of unknown origin. Despite extensive workup with cross-sectional imaging and panculture, the etiology was not found. Eventually, an 111In-labeled WBC scan was performed to evaluate for occult infection, which revealed intense heterogeneous uptake in the urinary bladder. Subsequent bladder catheterization showed pus and blood, which grew Klebsiella pneumoniae. The fevers resolved with adjustment of the therapy. Although urinary analysis and culture are standard practice in the workup of fever of unknown origin, anuria may obscure this common source of infection.
Asunto(s)
Radioisótopos de Indio/metabolismo , Leucocitos/metabolismo , Vejiga Urinaria/inmunología , Infecciones Urinarias/inmunología , Transporte Biológico , Femenino , Humanos , Persona de Mediana Edad , Coloración y Etiquetado , Infecciones Urinarias/metabolismoRESUMEN
AIMS/INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RA) are used for treatment of type 2 diabetes mellitus worldwide. However, some patients do not respond well to the therapy, and caution must be taken for certain patients, including those with reduced insulin secretory capacity. Thus, it is clinically important to predict the efficacy of GLP-1RA therapy. GLP-1R-targeted imaging has recently emerged to visualize and quantify ß-cells. We investigated whether GLP-1R-targeted imaging can predict the efficacy of GLP-1RA treatment. MATERIALS AND METHODS: We developed 111 Indium-labeled exendin-4 derivative (111 In-Ex4) as a GLP-1R-targeting probe. Diabetic mice were selected from NONcNZO10/LtJ male mice that were fed for different durations with 11% fat chow. After 3-week administration of dulaglutide as GLP-1RA therapy, mice with non-fasting blood glucose levels <300 mg/dL and >300 mg/dL were defined as responders and non-responders, respectively. In addition, ex vivo 111 In-Ex4 pancreatic accumulations (111 In-Ex4 pancreatic values) were examined. RESULTS: The non-fasting blood glucose levels after treatment were 172.5 ± 42.4 mg/dL in responders (n = 4) and 330.8 ± 20.7 mg/dL in non-responders (n = 5), respectively. Ex vivo 111 In-Ex4 pancreatic values showed significant correlations with post-treatment glycohemoglobin and glucose area under curve during an oral glucose tolerance test (R2 = 0.76 and 0.80; P < 0.01 and <0.01, respectively). The receiver operating characteristic area under curve for identifying responders by ex vivo 111 In-Ex4 pancreatic values was 1.00 (P < 0.01). CONCLUSION: Ex vivo 111 In-Ex4 pancreatic values reflected dulaglutide efficacy, suggesting clinical possibilities for expanding GLP-1R-targeted imaging applications.
Asunto(s)
Diabetes Mellitus Experimental/diagnóstico por imagen , Diabetes Mellitus Experimental/tratamiento farmacológico , Exenatida/farmacología , Receptor del Péptido 1 Similar al Glucagón/agonistas , Glucosa/metabolismo , Hipoglucemiantes/farmacología , Radioisótopos de Indio/metabolismo , Animales , Diabetes Mellitus Experimental/metabolismo , Diabetes Mellitus Experimental/patología , Células Secretoras de Insulina/efectos de los fármacos , Células Secretoras de Insulina/metabolismo , Células Secretoras de Insulina/patología , Masculino , RatonesRESUMEN
The withdrawal of Cr-chromate has meant that the technique commonly used for direct measurement of red cell volume has had to be replaced. Most centres moved to a Tc erythrocyte label, however, Tc is known to dissociate over time. We have investigated an alternative technique using an In-chloride and tropolone solution and tested this both in vitro and in vivo. Initial in-vitro and in-vivo work, which included a check of the stability of the radio-labelled product at one hour, demonstrated this label to be stable over this time period. To date, 20 patients have undergone this technique and results show that this technique is a viable alternative to Cr-chromate particularly for patients with splenomegaly who require late sampling. This procedure is now in routine use in our institution.
Asunto(s)
Radioisótopos de Cromo/metabolismo , Volumen de Eritrocitos , Radioisótopos de Indio/metabolismo , Marcaje Isotópico/métodos , HumanosRESUMEN
INTRODUCTION: Increased activity of matrix metalloproteases (MMPs) is associated with reduced survival in several cancer subtypes. Aiming to produce an MMP tumour cell-selective cytotoxin, we genetically modified both components of the AB-type lethal toxin from Bacillus anthracis. Component A, Protective Antigen (PA-WT), was re-engineered to form an oligomeric pore in cell membranes only when cleaved by MMPs (PA-L1). The pore-translocation domain (LFn - N-terminal, 30â¯kDa) of the Lethal Factor (LF), component B, was fused to the catalytic domain of Pseudomonas exotoxin-A to increase its cytotoxic effect when delivered to cancerous cells. Here, we develop radiolabelled forms of LFn for MMP activity imaging by SPECT using the LFn/PA-L1 system. METHODS: DOTA-GA-maleimide was conjugated to LFn to allow radiolabelling with 111In via two different routes: (1) LFn was conjugated with maleimide-DOTA-GA under mild conditions, and then radiolabelled in acidic conditions at 95°C, or (2) 111In was coordinated to maleimide-DOTA-GA first and then conjugated via maleimide chemistry to LFn. Circular Dichroism Spectroscopy of LFn was performed to evaluate changes in its secondary structure. Cell uptake assays using the differently labelled forms of [111In]In-DOTA-GA-LFn in the presence or not of PA-WT or PA-L1 were performed. RESULTS: LFn was successfully radiolabelled by either strategy. Comparison of the secondary structure content of LFn exposed to 37°C or 95°C, showed a loss of alpha helix content at higher temperatures. Cell uptake of both forms of [111In]In-DOTA-GA-LFn, labelled directly or indirectly, was significantly higher in MMP-positive cells, in the presence of PA-L1, compared to controls. Notably, despite being exposed to high temperatures, uptake of directly labelled [111In]In-DOTA-GA-LFndir was higher than indirectly labelled [111In]In-DOTA-GA-LFnindir. CONCLUSIONS: 111In-radiolabelling of LFn results in a functional molecule that targets MMP-activity in cells when combined with PA-L1. [111In]In-LFn/PA-L1 is a promising MMP activity imaging agent for SPECT imaging.
Asunto(s)
Antígenos Bacterianos/metabolismo , Toxinas Bacterianas/metabolismo , Neoplasias de la Mama/patología , Membrana Celular/metabolismo , Radioisótopos de Indio/metabolismo , Metaloproteinasas de la Matriz/metabolismo , Tomografía Computarizada de Emisión de Fotón Único/métodos , Antígenos Bacterianos/química , Toxinas Bacterianas/química , Neoplasias de la Mama/diagnóstico por imagen , Neoplasias de la Mama/metabolismo , Femenino , Humanos , Radioisótopos de Indio/química , Radiofármacos/química , Radiofármacos/metabolismo , Células Tumorales CultivadasRESUMEN
OBJECTIVE: Targeting the glucagon-like peptide-1 receptor with radiolabeled exendin is a very promising method to noninvasively determine the ß cell mass in the pancreas, which is needed to unravel the pathophysiology of type 1 and type 2 diabetes. The present study aimed to explore the effects of both hyperglycemia and insulitis on the uptake of exendin in a spontaneous type 1 diabetes mouse model, nonobese diabetic (NOD) mice. METHODS: NOD mice (n = 75, 7-21 weeks old) were injected intravenously with [111In]In-DTPA-exendin-3, and single-photon emission computed tomography (SPECT) images were acquired 1 h pi. The pancreatic accumulation of [111In]In-DTPA-exendin-3 was quantified in vivo using SPECT and by ex vivo counting and correlated to the ß cell mass (BCM). The influence of insulitis and hyperglycemia on the exendin uptake was assessed. RESULTS: The pancreas could be visualized longitudinally using SPECT. A linear correlation was found between the BCM (%) and pancreatic uptake (%ID/g) as measured by ex vivo counting (Pearson r = 0.64, p < 0.001), which was not affected by either insulitis (Pearson r = 0.66, p = 0.83) or hyperglycemia (Pearson r = 0.57, p = 0.51). Biodistribution and ex vivo autoradiography revealed remaining [111In]In-DTPA-exendin-3 uptake in the pancreas despite total ablation of BCM. CONCLUSIONS: Despite hyperglycemia and severe insulitis, we have found a good correlation between BCM and pancreatic exendin uptake, even in a suboptimal model with relatively high background activity.
Asunto(s)
Diabetes Mellitus Tipo 1/metabolismo , Hiperglucemia/metabolismo , Células Secretoras de Insulina/metabolismo , Péptidos/metabolismo , Tomografía Computarizada de Emisión de Fotón Único/métodos , Animales , Autorradiografía , Diabetes Mellitus Tipo 1/diagnóstico por imagen , Modelos Animales de Enfermedad , Femenino , Inmunohistoquímica , Radioisótopos de Indio/administración & dosificación , Radioisótopos de Indio/química , Radioisótopos de Indio/metabolismo , Inyecciones Intravenosas , Ratones , Ratones Endogámicos NOD , Ácido Pentético/administración & dosificación , Ácido Pentético/química , Ácido Pentético/metabolismo , Péptidos/administración & dosificación , Péptidos/química , Radiofármacos/metabolismo , Distribución TisularRESUMEN
BACKGROUND: 111In-DOTA-butylamino-NorBIRT (DANBIRT) is a novel radioligand which binds to Leukocyte Function-associated Antigen-1 (LFA-1), expressed on inflammatory cells. This study evaluated 111In-DANBIRT for the visualization of atherosclerotic plaque inflammation in mice. METHODS AND RESULTS: ApoE-/- mice, fed an atherogenic diet up to 20 weeks (n = 10), were imaged by SPECT/CT 3 hours post injection of 111In-DANBIRT (~ 200 pmol, ~ 40 MBq). Focal spots of 111In-DANBIRT were visible in the aortic arch of all animals, with an average Target-to-Background Ratio (TBR) of 1.7 ± 0.5. In vivo imaging results were validated by ex vivo SPECT/CT imaging, with a TBR up to 11.5 (range 2.6 to 11.5). Plaques, identified by Oil Red O lipid-staining on excised arteries, co-localized with 111In-DANBIRT uptake as determined by ex vivo autoradiography. Subsequent histological processing and in vitro autoradiography confirmed 111In-DANBIRT uptake at plaque areas containing CD68 expressing macrophages and LFA-1 expressing inflammatory cells. Ex vivo incubation of a human carotid endarterectomy specimen with 111In-DANBIRT (~ 950 nmol, ~ 190 MBq) for 2 hours showed heterogeneous plaque uptake on SPECT/CT, after which immunohistochemical analysis demonstrated co-localization of 111In-DANBIRT uptake and CD68 and LFA-1 expressing cells. CONCLUSIONS: Our results indicate the potential of radiolabeled DANBIRT as a relevant imaging radioligand for non-invasive evaluation of atherosclerotic inflammation.
Asunto(s)
Hidantoínas/metabolismo , Radioisótopos de Indio/metabolismo , Antígeno-1 Asociado a Función de Linfocito/metabolismo , Placa Aterosclerótica/diagnóstico por imagen , Animales , Antígenos CD/metabolismo , Antígenos de Diferenciación Mielomonocítica/metabolismo , Compuestos Azo/farmacología , Femenino , Inmunohistoquímica , Inflamación/diagnóstico por imagen , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados para ApoE , Tomografía Computarizada por Tomografía Computarizada de Emisión de Fotón ÚnicoRESUMEN
Neuroendocrine tumors (NET) are the rare tumors which often impose graveyard threat. These tumors are characterized by the over expression of various G-protein coupled receptors including cholecystokinin (CCK) receptors-1 and 2 (A or B). Minigastrin peptides are being investigated for theranostic purposes of CCK-2 receptor positive NET. The minigastrin analogue (APHO70) was modified by engineering enzyme susceptible tetrapeptide sequence into APHO70 peptide to reduce the random degradation by lysosome enzymes which pave the way to random trafficking in patient's body and dipeptide addition at c-terminus. All the four modified minigastrin peptides (MG-CL1-4) were investigated for lysosome cathepsin B (catB) enzyme susceptibility and fate into AR42J cancer cell line. The indium-111 labeled MG-CL1-4 peptides were also studied for target (tumor) and non-target saccumulation by using tumor induced mice. The RP-HPLC analysis result showed nonspecific cleavage of standard 111In-APH070 and 111In-MGCL1 while specific cleavage was noted in case of 111In-MGCL (2-4). The effect of specific and non-specific cleavage on biodistribution in tumor induced nude mice model indicates the promising accumulation of 111In-MGCL2, 111In-MGCL3, and 111In-MGCL4 radiotracers while 111In-MGCL1 showed less accumulation. 111In-MGCL2 and 111In-MGCL3 showed highest target-to-kidney ratio (T/K) i.e. 1.71 and 1.72, respectively whereas standard compound showed T/K 1.13. In conclusion, the two indium-111 labeled analogues i.e. 111In-MGCL2 and 111In-MGCL3 showed promising sensitivity for tumor andcould be tested for further investigation to reach pre-clinical studies.
Asunto(s)
Catepsina B/metabolismo , Gastrinas/metabolismo , Radioisótopos de Indio/metabolismo , Tumores Neuroendocrinos/metabolismo , Fragmentos de Péptidos/metabolismo , Radiofármacos/metabolismo , Animales , Línea Celular Tumoral , Femenino , Ratones , Ratones Desnudos , Tumores Neuroendocrinos/diagnóstico por imagenRESUMEN
Radionuclide molecular imaging is a promising tool for visualization of cancer associated molecular abnormalities in vivo and stratification of patients for specific therapies. ADAPT is a new type of small engineered proteins based on the scaffold of an albumin binding domain of protein G. ADAPTs have been utilized to select and develop high affinity binders to different proteinaceous targets. ADAPT6 binds to human epidermal growth factor 2 (HER2) with low nanomolar affinity and can be used for its in vivo visualization. Molecular design of 111In-labeled anti-HER2 ADAPT has been optimized in several earlier studies. In this study, we made a direct comparison of two of the most promising variants, having either a DEAVDANS or a (HE)3DANS sequence at the N-terminus, conjugated with a maleimido derivative of DOTA to a GSSC amino acids sequence at the C-terminus. The variants (designated DOTA-C59-DEAVDANS-ADAPT6-GSSC and DOTA-C61-(HE)3DANS-ADAPT6-GSSC) were stably labeled with 111In for SPECT and 68Ga for PET. Biodistribution of labeled ADAPT variants was evaluated in nude mice bearing human tumor xenografts with different levels of HER2 expression. Both variants enabled clear discrimination between tumors with high and low levels of HER2 expression. 111In-labeled ADAPT6 derivatives provided higher tumor-to-organ ratios compared to 68Ga-labeled counterparts. The best performing variant was DOTA-C61-(HE)3DANS-ADAPT6-GSSC, which provided tumor-to-blood ratios of 208 ± 36 and 109 ± 17 at 3 h for 111In and 68Ga labels, respectively.
Asunto(s)
Proteínas Bacterianas/química , Diseño de Fármacos , Imagen Molecular/métodos , Neoplasias/diagnóstico por imagen , Receptor ErbB-2/metabolismo , Animales , Proteínas Bacterianas/administración & dosificación , Proteínas Bacterianas/genética , Proteínas Bacterianas/metabolismo , Línea Celular Tumoral , Femenino , Radioisótopos de Galio/administración & dosificación , Radioisótopos de Galio/química , Radioisótopos de Galio/metabolismo , Humanos , Radioisótopos de Indio/administración & dosificación , Radioisótopos de Indio/química , Radioisótopos de Indio/metabolismo , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Neoplasias/patología , Ingeniería de Proteínas , Cintigrafía/métodos , Proteínas Recombinantes/administración & dosificación , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Distribución Tisular , Ensayos Antitumor por Modelo de XenoinjertoRESUMEN
Recent advances in oncology involve the use of diagnostic/therapeutic radionuclide-carrier pairs that target cancer cells, offering exciting opportunities for personalized patient treatment. Theranostic gastrin-releasing peptide receptor (GRPR)-directed radiopeptides have been proposed for the management of GRPR-expressing prostate and breast cancers. We have recently introduced the PET tracer 68Ga-SB3 (SB3, DOTA- p-aminomethylaniline-diglycolic acid-DPhe-Gln-Trp-Ala-Val-Gly-His-Leu-NHEt), a receptor-radioantagonist that enables the visualization of GRPR-positive lesions in humans. Aiming to fully assess the theranostic potential of SB3, we herein report on the impact of switching 68Ga to 111In/177Lu-label on the biological properties of resulting radiopeptides. Notably, the bioavailability of 111In/177Lu-SB3 in mice drastically deteriorated compared with metabolically robust 68Ga-SB3, and as a result led to poorer 111In/177Lu-SB3 uptake in GRPR-positive PC-3 xenografts. The peptide cleavage sites were identified by chromatographic comparison of blood samples from mice intravenously receiving 111In/177Lu-SB3 with each of newly synthesized 111In/177Lu-SB3-fragments. Coinjection of the radioconjugates with the neprilysin (NEP)-inhibitor phosphoramidon led to full stabilization of 111In/177Lu-SB3 in peripheral mouse blood and resulted in markedly enhanced radiolabel uptake in the PC-3 tumors. In conclusion, in situ NEP-inhibition led to indistinguishable 68Ga/111In/177Lu-SB3 profiles in mice emphasizing the theranostic prospects of SB3 for clinical use.
Asunto(s)
Complejos de Coordinación/farmacocinética , Radioisótopos de Indio/farmacocinética , Lutecio/farmacocinética , Neprilisina/farmacocinética , Oligopéptidos/farmacocinética , Neoplasias de la Próstata/diagnóstico por imagen , Radioisótopos/farmacocinética , Receptores de Bombesina/análisis , Animales , Complejos de Coordinación/química , Complejos de Coordinación/metabolismo , Humanos , Radioisótopos de Indio/química , Radioisótopos de Indio/metabolismo , Lutecio/química , Lutecio/metabolismo , Masculino , Ratones , Neprilisina/química , Neprilisina/metabolismo , Oligopéptidos/química , Oligopéptidos/metabolismo , Células PC-3 , Tomografía de Emisión de Positrones/métodos , Radioisótopos/química , Radioisótopos/metabolismo , Receptores de Bombesina/antagonistas & inhibidores , Nanomedicina Teranóstica/métodos , Distribución TisularRESUMEN
A new modular nanotransporter (MNT) for the delivery of anticancer agents into the nuclei of cells with folate receptor overexpression was created. An effective method for acceding labeling of this MNT with Auger electron emitter 111In has been developed. A significant therapeutic effect was observed after a single intratumoral injection of the new 111In-labeled MNT to mice grafted with human cervical carcinoma characterized by folate receptor overexpression.
Asunto(s)
Núcleo Celular/metabolismo , Electrones , Transportadores de Ácido Fólico/metabolismo , Regulación Neoplásica de la Expresión Génica , Radioisótopos de Indio/metabolismo , Radioisótopos de Indio/uso terapéutico , Animales , Células HeLa , Humanos , Radioisótopos de Indio/administración & dosificación , RatonesRESUMEN
A 79-year-old man with history of aortic stenosis, status post bioprosthetic aortic valve replacement, episodes of bacteremia, and endocarditis presented to hospital with fever. Clinical assessment led to suspicion of possible endocarditis. Initial interpretation of transesophageal echocardiogram was inconclusive without vegetation in mitral/aortic valve. An In-leukocyte scan demonstrated increased uptake in the area of aortic valve, suggestive of infection. Further review of the transesophageal echocardiogram showed signs of annular abscess. This case highlights that combination of echocardiography with white blood cell imaging increases the sensitivity to detect endocarditis/perivalvular abscess.
Asunto(s)
Absceso/diagnóstico por imagen , Aorta/diagnóstico por imagen , Ecocardiografía Transesofágica , Radioisótopos de Indio/metabolismo , Leucocitos/metabolismo , Absceso/sangre , Anciano , Humanos , MasculinoRESUMEN
Fibroblast growth factor-2 (FGF-2) is a potent modulator of cell growth and regulation, with improper FGF-2 signaling being involved in impaired responses to injury or even cancer. Therefore, the exploitation of FGF-2 as a therapeutic drives the prerequisite for effective insight into drug disposition kinetics. In this article, we present an 111In-radiolabeled FGF-2 derivative for noninvasive imaging in small animals deploying single photon emission tomography (SPECT). 111In-FGF-2 is equally well suitable for in vitro and ex vivo investigations as 125I-FGF-2. Furthermore, 111In-FGF-2 permits the performance of in vivo imaging, for example for the analysis of FGF-2 containing pharmaceutical formulations in developmental or preclinical stages. 111In-FGF-2 had affinity for the low-molecular-weight heparin enoxaparin identical to that of unlabeled FGF-2 (Kd: 0.6 ± 0.07 µM and 0.33 ± 0.03 µM, respectively) as assessed by isothermal titration calorimetry. The binding of 111In-FGF-2 to heparan sulfate proteoglycans (HPSGs) and the biological activity were comparable to those of unlabeled FGF-2, with EC50 values of 12 ± 2 pM and 25 ± 6 pM, respectively. In vivo biodistribution in healthy nude mice indicated a predominant accumulation of 111In-FGF-2 in filtering organs and minor uptake in the retina and the salivary and pituitary glands, which was confirmed by SPECT imaging. Therefore, 111In-FGF-2 is a valid tracer for future noninvasive animal imaging of FGF-2 in pharmaceutical development.
Asunto(s)
Factor 2 de Crecimiento de Fibroblastos/metabolismo , Radioisótopos de Indio/metabolismo , Animales , Proteoglicanos de Heparán Sulfato/metabolismo , Heparina de Bajo-Peso-Molecular/metabolismo , Humanos , Cinética , Ratones , Ratones Desnudos , Células 3T3 NIH , Unión Proteica/fisiología , Distribución Tisular/fisiología , Tomografía Computarizada de Emisión de Fotón Único/métodosRESUMEN
Radiolabeled exendin is used for non-invasive quantification of beta cells in the islets of Langerhans in vivo. High accumulation of radiolabeled exendin in the islets raised concerns about possible radiation-induced damage to these islets in man. In this work, islet absorbed doses resulting from exendin-imaging were calculated by combining whole organ dosimetry with small scale dosimetry for the islets. Our model contains the tissues with high accumulation of radiolabeled exendin: kidneys, pancreas and islets. As input for the model, data from a clinical study (radiolabeled exendin distribution in the human body) and from a preclinical study with Biobreeding Diabetes Prone (BBDP) rats (islet-to-exocrine uptake ratio, beta cell mass) were used. We simulated 111In-exendin and 68Ga-exendin absorbed doses in patients with differences in gender, islet size, beta cell mass and radiopharmaceutical uptake in the kidneys. In all simulated cases the islet absorbed dose was small, maximum 1.38 mGy for 68Ga and 66.0 mGy for 111In. The two sources mainly contributing to the islet absorbed dose are the kidneys (33-61%) and the islet self-dose (7.5-57%). In conclusion, all islet absorbed doses are low (<70 mGy), so even repeated imaging will hardly increase the risk on diabetes.
Asunto(s)
Células Secretoras de Insulina/patología , Islotes Pancreáticos/patología , Riñón/metabolismo , Traumatismos por Radiación/diagnóstico , Radiometría/métodos , Adulto , Animales , Recuento de Células , Diabetes Mellitus/etiología , Diabetes Mellitus/genética , Modelos Animales de Enfermedad , Femenino , Radioisótopos de Galio/química , Radioisótopos de Galio/metabolismo , Humanos , Radioisótopos de Indio/química , Radioisótopos de Indio/metabolismo , Células Secretoras de Insulina/metabolismo , Células Secretoras de Insulina/efectos de la radiación , Péptidos y Proteínas de Señalización Intercelular , Islotes Pancreáticos/metabolismo , Islotes Pancreáticos/efectos de la radiación , Riñón/efectos de la radiación , Masculino , Persona de Mediana Edad , Péptidos/química , Péptidos/metabolismo , Radiación , Dosis de Radiación , Ratas , Ratas Mutantes , Adulto JovenRESUMEN
Thromboembolic disorders are a major cause of morbidity and mortality worldwide. The progress in noninvasive imaging techniques has led to the development of radionuclide imaging based on SPECT and PET approaches to observe molecular and cellular processes that may underlie the onset and progression of disease. The advantages of using normal and genetically modified small animal research have spurred the development of dedicated small animal imaging systems. Animal models of venous and arterial thrombosis are largely used and have improved our understanding of the etiology and pathogenesis of thrombosis. Here, we review the literature regarding nuclear imaging of thrombosis in mice and rats.
Asunto(s)
Plaquetas/metabolismo , Tomografía de Emisión de Positrones/métodos , Tromboembolia/diagnóstico por imagen , Trombosis/diagnóstico por imagen , Tomografía Computarizada de Emisión de Fotón Único/métodos , Animales , Plaquetas/patología , Modelos Animales de Enfermedad , Fluorodesoxiglucosa F18/metabolismo , Fluorodesoxiglucosa F18/farmacocinética , Humanos , Radioisótopos de Indio/metabolismo , Radioisótopos de Indio/farmacocinética , Ligandos , Ratones , Compuestos de Organotecnecio/metabolismo , Compuestos de Organotecnecio/farmacocinética , Fosfatidilserinas/metabolismo , Activación Plaquetaria , Complejo GPIIb-IIIa de Glicoproteína Plaquetaria/metabolismo , Tomografía de Emisión de Positrones/instrumentación , Radiofármacos/metabolismo , Radiofármacos/farmacocinética , Ratas , Tromboembolia/metabolismo , Tromboembolia/patología , Trombosis/metabolismo , Trombosis/patología , Tomografía Computarizada de Emisión de Fotón Único/instrumentaciónRESUMEN
The metabolic instability and high kidney retention of minigastrin (MG) analogues hamper their suitability for use in peptide-receptor radionuclide therapy of CCK2/gastrin receptor-expressing tumors. High kidney retention has been related to N-terminal glutamic acids and can be substantially reduced by coinjection of polyglutamic acids or gelofusine. The aim of the present study was to investigate the influence of the stereochemistry of the N-terminal amino acid spacer on the enzymatic stability and pharmacokinetics of (111)In-DOTA-(d-Glu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 ((111)In-PP11-D) and (111)In-DOTA-(l-Glu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2 ((111)In-PP11-L). Using circular dichroism measurements, we demonstrate the important role of secondary structure on the pharmacokinetics of the two MG analogues. The higher in vitro serum stability together with the improved tumor-to-kidney ratio of the (d-Glu)6 congener indicates that this MG analogue might be a good candidate for further clinical study.
Asunto(s)
Gastrinas/farmacocinética , Compuestos Heterocíclicos con 1 Anillo/farmacocinética , Radioisótopos de Indio/farmacocinética , Neoplasias/diagnóstico por imagen , Receptor de Colecistoquinina B/metabolismo , Receptor de Colecistoquinina B/fisiología , Secuencia de Aminoácidos , Animales , Gastrinas/química , Gastrinas/metabolismo , Compuestos Heterocíclicos con 1 Anillo/química , Compuestos Heterocíclicos con 1 Anillo/metabolismo , Humanos , Radioisótopos de Indio/química , Radioisótopos de Indio/metabolismo , Masculino , Neoplasias/diagnóstico , Neoplasias/metabolismo , Tomografía de Emisión de Positrones , Ratas Endogámicas LewRESUMEN
Antibodies that block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive antitumor activity. Patients with tumors expressing PD-L1 are most likely to respond to this treatment. The aim of our study was to develop a noninvasive imaging technique to determine tumor PD-L1 expression in vivo. This could allow selection of patients that are most likely to benefit from anti-PD-1/PD-L1 treatment and to monitor PD-L1 expression during therapy. The monoclonal antibody PD-L1.3.1 was radiolabeled with Indium-111 ((111)In) and characterized using PD-L1-expressing MDA-MB-231 cells. Subsequently, the optimal antibody dose and time point for imaging was determined in mice with MDA-MB-231 xenografts. Finally, SPECT/CT imaging was performed in xenograft models with different PD-L1 expression levels and tumor sections were analyzed for PD-L1 expression using IHC. The optimal antibody dose of (111)In-PD-L1.3.1 (Kd = 1 nmol/L) for SPECT/CT imaging was ≤1 µg. Highest tumor-to-normal tissue contrast was obtained at days 3 and 7 after injection. (111)In-PD-L1.3.1 SPECT/CT showed efficient accumulation in high PD-L1-expressing tumors (MDA-MB-231 and SK-Br-3), whereas no specific uptake was observed in tumors with low or no detectable levels of PD-L1 (SUM149, BT474, and MCF-7). SPECT/CT and autoradiography showed a very heterogeneous distribution of (111)In-PD-L1.3.1 within the tumor. In conclusion, this is the first study showing the feasibility of noninvasive in vivo imaging of PD-L1 expression in tumors. (111)In-PD-L1.3.1 showed efficient and specific uptake in PD-L1 expressing xenografts. This technique may enable patient selection for PD-1 and PD-L1-targeted therapy.
Asunto(s)
Anticuerpos Monoclonales , Antígeno B7-H1/inmunología , Antígeno B7-H1/metabolismo , Neoplasias de la Mama/diagnóstico por imagen , Radioisótopos de Indio , Tomografía Computarizada de Emisión de Fotón Único/métodos , Animales , Neoplasias de la Mama/metabolismo , Neoplasias de la Mama/patología , Femenino , Xenoinjertos , Humanos , Radioisótopos de Indio/metabolismo , Células MCF-7 , Ratones , Ratones Endogámicos BALB C , Trasplante de Neoplasias , Unión Proteica , Distribución Tisular , Células Tumorales CultivadasRESUMEN
Microdosimetric evaluation of Auger electron-emitting radionuclides involves a detailed evaluation of energy deposition at a nanometre scale. To perform Monte Carlo modelling of such energy deposition, accurate information regarding the spatial distribution of the radionuclide is required. A recent addition to the methods for determining the spatial distribution of cellular internalised radionuclides is based on detection in a polymer photoresist (e.g. polymethyl methacralate), followed by atomic force microscopy analysis of the resultant 3D pattern. In comparison with present practice, the method offers greater spatial resolution and improved quantification. The volume of the pattern is proportional to the total dose, thereby permitting assessment of variability of accumulated activity, while the variation in depth across the pattern reflects the lateral spatial distribution in the local fluence per unit area. An added advantage is the similarity in response to ionising radiation of an organic polymer compared to that of biological material. A pattern in the resist from radiation emitted by a radionuclide treated cell gives additional spatial information about the energy deposited in the resist.
Asunto(s)
Autorradiografía , Carcinoma de Células Escamosas/diagnóstico por imagen , Electrones , Neoplasias de Cabeza y Cuello/diagnóstico por imagen , Radioisótopos de Indio/metabolismo , Microscopía de Fuerza Atómica/métodos , Humanos , Polimetil Metacrilato/química , Polimetil Metacrilato/efectos de la radiación , Cintigrafía , Células Tumorales CultivadasRESUMEN
UNLABELLED: The overexpression and excessive signaling of platelet-derived growth factor receptor ß (PDGFRß) has been detected in cancers, atherosclerosis, and a variety of fibrotic diseases. Radionuclide in vivo visualization of PDGFRß expression might help to select PDGFRß targeting treatment for these diseases. The goal of this study was to evaluate the feasibility of in vivo radionuclide imaging of PDGFRß expression using an Affibody molecule, a small nonimmunoglobulin affinity protein. METHODS: The PDGFRß-binding Z09591 Affibody molecule was site-specifically conjugated with a maleimido derivative of DOTA and labeled with (111)In. Targeting of the PDGFRß-expressing U-87 MG glioblastoma cell line using (111)In-DOTA-Z09591 was evaluated in vitro and in vivo. RESULTS: DOTA-Z09591 was stably labeled with (111)In with preserved specific binding to PDGFRß-expressing cells in vitro. The dissociation constant for (111)In-DOTA-Z09591 binding to U-87 MG cells was determined to be 92 ± 10 pM. In mice bearing U-87 MG xenografts, the tumor uptake of (111)In-DOTA-Z09591 was 7.2 ± 2.4 percentage injected dose per gram and the tumor-to-blood ratio was 28 ± 14 at 2 h after injection. In vivo receptor saturation experiments demonstrated that targeting of U-87 MG xenografts in mice was PDGFRß-specific. U-87 MG xenografts were clearly visualized using small-animal SPECT/CT at 3 h after injection. CONCLUSION: This study demonstrates the feasibility of in vivo visualization of PDGFRß-expressing xenografts using an Affibody molecule. Further development of radiolabeled Affibody molecules might provide a useful clinical imaging tool for PDGFRß expression during various pathologic conditions.